TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06202261
Drug: Eribulin mesylate injection
Normalized name: Eribulin Mesylate Injection
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
Study: NCT06202261
Drug: gemcitabine hydrochloride for injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
Study: NCT06573489
Drug: Fospropofol
Normalized name: Fospropofol
DrugBank: Fospropofol (DB06716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use fospropofol for general anesthesia maintenance
Study: NCT06573489
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use propofol for general anesthesia maintenance
Study: NCT05420012
Drug: Vericiguat
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Study: NCT05717738
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg; p.o.; q.d.
Study: NCT05717738
Drug: Anti-PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Study: NCT05717738
Drug: Bevacizumab Biosimilar IBI305 plus sintilimab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Study: NCT05717738
Drug: Bevacizumab plus Atezolizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
Study: NCT05717738
Drug: apatinib plus camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
Study: NCT05717738
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg; p.o. bid
Study: NCT05717738
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg; p.o. bid
Study: NCT05717738
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 mg; p.o.; q.d.
Study: NCT05396118
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
Study: NCT04541823
Drug: Desﬂurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
Study: NCT04541823
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
Study: NCT05816356
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of decitabine as a single dose to healthy male subjects
Study: NCT05816356
Drug: Tetrahydrouridine
Normalized name: Tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
Study: NCT05278793
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate 200mg oral
Study: NCT06527300
Drug: NHWD-870 HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered P.O.
Study: NCT06070610
Drug: BI 1015550
Normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1015550
Study: NCT06070610
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Soft capsules
Study: NCT06070610
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablets
Study: NCT05870475
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
Study: NCT05870475
Drug: Pegylated interferon α-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
Study: NCT00486980
Drug: Peramivir 150mg
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00486980
Drug: Peramivir 300mg
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05465174
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05465174
Drug: Tovorafenib
Normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT05211050
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 min infusion of 4 mg sumatriptan.
Study: NCT05211050
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 min infusion of isotonic saline (placebo).
Study: NCT04661137
Drug: Selinexor 60 MG
Normalized name: selinexor 60 MG
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 60 mg PO on days 1, 8 and 15
Study: NCT04661137
Drug: Selinexor 80 MG
Normalized name: selinexor 80 mg/week (20 mg x 4) ORAL TABLET
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 80 mg PO on days 1, 8 and 15
Study: NCT04661137
Drug: Selinexor 100 MG
Normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 100 mg PO on days 1, 8, 15 and 22
Study: NCT04661137
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 56 mg/m2 IV on days 1, 8 and 15
Study: NCT04661137
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg PO daily for 21 days
Study: NCT04661137
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
Study: NCT04661137
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
Study: NCT04679389
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered orally or enterally
Study: NCT05616390
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV d1,Q3W
Study: NCT05616390
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg IV d1,Q3W
Study: NCT05152472
Drug: Atezolizumab 1200 mg
Normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Intravenous administration)
Study: NCT05152472
Drug: Imatinib 400 MG
Normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: (Per os)
Study: NCT05980026
Drug: oral omega-3 fatty acids supplementation
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral omega-3 fatty acids supplementation
Study: NCT05662306
Drug: Aripiprazole Lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
Study: NCT06411379
Drug: Sonelokimab
Normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonelokimab
Study: NCT06671379
Drug: SHR-A2009 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
Study: NCT06671379
Drug: platinum-based dual-agent chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
Study: NCT06671496
Drug: Zasocitinib
Normalized name: Zasocitinib
DrugBank: Zasocitinib (DB19278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zasocitinib tablets.
Study: NCT06560268
Drug: Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
Study: NCT05148494
Drug: Pico-Salax
Normalized name: SALIX
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard pre-op application, see arm description
Study: NCT04776369
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single-bolus of lidocaine IV 4 mg/kg
Study: NCT04776369
Drug: Magnesium Sulfate Injection
Normalized name: magnesium sulfate Injection
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single-bolus of magnesium sulfate IV 30 mg / kg
Study: NCT05652660
Drug: ARV-471
Normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT05008510
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan-hziy
Study: NCT05008510
Drug: Sabizabulin/Sacituzumab govitecan-hziy Combo
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
Study: NCT00994916
Drug: 3,4 diaminopyridine
Normalized name: 3,4 diaminopyridine
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3,4 diaminopyridine up to 80 mg daily in divided doses
Study: NCT00002408
Drug: Crofelemer
Normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00548821
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00053612
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05581576
Drug: Pitolisant
Normalized name: pitolisant
DrugBank: Pitolisant (DB11642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
Study: NCT06184581
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
Study: NCT06184581
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
Study: NCT06058234
Drug: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
Study: NCT06531525
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Study: NCT06531525
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Study: NCT06531525
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
Study: NCT04841668
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
Study: NCT04889703
Drug: 30% Salicylic acid peel
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
Study: NCT04943900
Drug: BMS-986416
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04943900
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT04737122
Drug: LM-061
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
Study: NCT04737122
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
Study: NCT05781399
Drug: JNT-517 Suspension
Normalized name: JNT-517
DrugBank: JNT-517 (DB19305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNT-517 in on-site compounded suspension
Study: NCT05781399
Drug: JNT-517 Tablet
Normalized name: JNT-517
DrugBank: JNT-517 (DB19305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNT-517 tablets, 25 mg and 75 mg
Study: NCT05485012
Drug: Marijuana
Normalized name: Marijuana
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind administration of marijuana
Study: NCT05113004
Drug: Hydroxychloroquine 400mg/d
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
Study: NCT05113004
Drug: Leflunomide 20mg/d
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
Study: NCT05113004
Drug: Placebo of Hydroxychloroquine 400mg/d
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
Study: NCT05113004
Drug: Placebo of Leflunomide 20mg/d
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
Study: NCT06017284
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 100 mg/day, once a day, orally intake at night.
Study: NCT04824872
Drug: Dasiglucagon
Normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dasiglucagon SC, low dose
Study: NCT04824872
Drug: Dasiglucagon
Normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dasiglucagon SC, high dose
Study: NCT06017284
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.
Study: NCT06017284
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.
Study: NCT06054906
Drug: sintilimab+metronomic PLOF
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles
Study: NCT05256641
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05926258
Drug: Chloroprocaine 3% eye gel
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ocular surface anesthesia
Study: NCT06155916
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
Study: NCT06004037
Drug: Delpazolid
Normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total.
Study: NCT04579679
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300 mg oral once daily
Study: NCT05520749
Drug: Luspatercept
Normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
Study: NCT06290583
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia with standard dose of bupivacaine
Study: NCT06290583
Drug: Prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia with 50 mg dose of Prilocaine.
Study: NCT04804553
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive apremilast orally.